Abstract

1, 3, 4-OXADIAZOLE AS VEGFR INHIBITOR IN THE DEVELOPMENT OF ANTICANCER AGENT

Shilpa S. Kurup*

ABSTRACT

Oxadiazole is a pharmacologically active five-membered heterocyclic aromatic lead molecule. In the market, derivatives of oxadiazole (Tiodazosin, Nosapidil, Furamizole) are used in the preparation of dyes, liquid crystals, and scintillators, among other things. In this article, the results of many derivatives of different oxadiazoles and their substitutions with anticancer activity are reviewed. Following a brief historical overview, give a comprehensive overview of recent advancements in the synthesis of 1,3,4-oxadiazole-based compounds and key breakthroughs in their biological applications, as well as brief observations on future development prospects. The continuous expansion of angiogenesis inhibitors as cancer therapeutics is just another example of how a basic understanding of physiological processes can lead to innovative treatments. VEGF has been found to play a significant role in angiogenesis, tumour growth, and metastasis signalling pathways. As a result, anti-VEGF or anti-VEGF receptor medications have a great deal of potential in the treatment of cancer. Malignant tumours growth and metastatic spread are aided by the formation of a vascular supply. The most essential of the several growth factors that regulate normal and pathological angiogenesis is vascular endothelial growth factor (VEGF). At least in some cancers, there is evidence that VEGF overexpression is linked to a poor prognosis. Tumor-expressed VEGF is particularly appealing as a target for anticancer therapy since its angiogenesis-promoting activity occurs at the level of the endothelial cell, and tumour penetration is less important for VEGF inhibitors than for therapies that directly target tumour cells.

Keywords: Oxadiazole, Anticancer, Review.